Novavax, Inc. (NVAX) — closed signal from March 9, 2026
Partial Published before the outcome was known, scored automatically when the window closed on June 7, 2026 — -9.7% at the close.
Predicted vs. what happened
What happened
Reached 44% of the predicted growth at its peak, without hitting the target.
The thesis — published March 9, 2026
Recent news turned Novavax from a hopeful idea into a company that is actually making money now. Unexpected profit, growing license payments, and a contract with Pfizer give clearer cash flow. Trading interest is still healthy, but changes at the FDA can quickly change sentiment, so treat this as a short-term, sized trade for accounts that can handle risk.
Primary drivers
- Unexpected profit and licensing make near-term cash clearer
- Royalties from Pfizer and Sanofi improve predictable cash flow
- Trading interest stayed strong after the recent rise in price
- Positive vaccine updates could lift the stock even if market is flat
How it played out
NVAX: target was not reached
Lyra published NVAX on 2026-03-09 at $10.51, with expected growth of 24% and a target of $13.03. The thesis pointed to unexpected profit and licensing, royalties from Pfizer and Sanofi, healthy trading interest after the recent rise, and possible vaccine updates as short-term drivers.
Inside the 2026-03-09 to 2026-06-07 window, NVAX rose to a peak of $11.61 on 2026-05-27, a 10.5% gain. It stayed below the $13.03 target and never reached it. The stock ended at $9.49. The thesis partially played out, but missed the target.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.